The authors sought to provide the pre-specified primary endpoint of the ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients) trial at 2 years.The ROADMAP trial was a prospective nonrandomized observational study of 200 patients (97 with a left ventricular assist device [LVAD], 103 on optimal medical management [OMM]) that showed that survival with improved functional status at 1 year was better with LVADs compared with OMM in a patient population of ambulatory New York Heart Association functional class IIIb/IV patients.The primary composite endpoint was survival on original therapy with improvement in 6-min walk distance ≥75 m.Patients receiving LVAD versus OMM had lower baseline health-related quality of life, reduced Seattle Heart Failure Model 1-year survival (78

作者：Randall C, Starling；Jerry D, Estep；Douglas A, Horstmanshof；Carmelo A, Milano；Josef, Stehlik；Keyur B, Shah；Brian A, Bruckner；Sangjin, Lee；James W, Long；Craig H, Selzman；Vigneshwar, Kasirajan；Donald C, Haas；Andrew J, Boyle；Joyce, Chuang；David J, Farrar；Joseph G, Rogers

来源：JACC. Heart failure 2017 年 5卷 7期